Organigram Announces Proposed Acquisition of Sanity Group, a Leading German Cannabis Company Accretive Acquisition of Sanity Group Establishes Organigram as a Global Pure Play Cannabis Company with Leadership Positions in the World’s Two Largest…
Organigram Announces Proposed Acquisition of Sanity
Group, a Leading German Cannabis Company
Accretive Acquisition of Sanity Group Establishes Organigram as a Global Pure
Play Cannabis Company with Leadership Positions in the World’s Two Largest
Federally Legal Cannabis Markets
• Organigram to acquire Sanity Group for up-front consideration of €113.4
million plus a maximum earnout of up to €113.8 million tied to financial
performance.
• Proposed Acquisition of the Berlin‑based company unites two leaders in the
largest federally legal cannabis markets, boosting commercial opportunities,
strengthening access to best‑in‑class leadership, and expanding a valuable
network of supply-chain partners.
• Sanity is achieving top-line growth. Annual net revenue increased from €9
million in 2023 to €60 million in 2025, including €19 million generated in the
fourth quarter of 2025.
• Sanity Group operates Europe’s first two legal cannabis specialty stores as
part of scientific pilot projects in Switzerland.
• Opportunity to capitalize on Sanity’s near-term plans to enter the UK and
Poland markets and expand on existing business in Czechia.
• Opportunity to bring industry-leading IP generated by the Product
Development Collaboration (PDC) as well as Organigram’s products to
emerging legal cannabis markets.
• Organigram poised to sell significantly greater volumes of higher-margin
flower into Europe with the ability to capture more of the value chain.
• Acquisition is expected to be financed by a combination of cash on hand,
proceeds from a new credit facility, and expected C$65.2 million equity
investment by BAT.
Toronto, Ontario, February 18, 2026 – Organigram Global Inc. (NASDAQ: OGI) (TSX:
OGI), (the “Company” or “Organigram”), a leading licensed producer of cannabis, is
pleased to announce that it has entered into a definitive agreement (the “Purchase
Agreement”) to acquire (the “Acquisition”) all the issued and outstanding shares of Sanity
Group GmbH (“Sanity” or “Sanity Group”) not currently owned by Organigram.
Upon closing of the Acquisition, Organigram will pay shareholders of Sanity (collectively,
the “Vendors”) upfront consideration of €113.4 million consisting of €80.0 million cash
1
and share consideration of €33.4 million in Organigram shares (the “Upfront
Consideration”). In addition, the Vendors will be entitled to receive consideration of up to
€113.8 million, with the first €20 million in cash
1
and up to €93.8 million in Organigram
shares (“Earnout Consideration”) based on Sanity’s financial performance for the 12-
month period following the closing. The Upfront Consideration shares are expected to be
priced at C$3.00 per Organigram share, representing a 71% premium to the C$1.75
closing price on the Toronto Stock Exchange (“TSX”) on February 17, 2026. The Earnout
Consideration shares shall be priced at the TSX 20-day VWAP on the trading day prior
to settlement, subject to a C$3.00 floor and C$4.00 cap.
“The proposed acquisition of Sanity Group marks a pivotal step in Organigram's global
expansion strategy as a leader in the rapidly expanding cannabis industry,” said James
Yamanaka, CEO of Organigram. “This transformational acquisition will bring together two
market leaders, extend our commercial footprint into Europe, and strengthen our
competitive edge in the world’s largest federally legal cannabis markets.”
Sanity Group Overview
Berlin-based Sanity Group, founded in 2018, is one of Europe’s most prominent and
respected cannabis companies. Sanity Group has established a reputation for leadership
across several key market segments, including medical cannabis, recreational pilot
1
BAT has opted to take Organigram shares in lieu of cash for its interest in Sanity.
programs, and wellbeing products. Sanity Group is led by co-founder and CEO Finn Age
Hänsel, supported by a seasoned executive management team.
The team brings expertise in entrepreneurship, operational efficiency, scaling operations,
logistics, and brand development.
Sanity Group’s portfolio of leading brands reflects a strong commitment to excellence and
innovation, securing its position at the forefront of growth within the rapidly expanding
European cannabis sector.
Sanity Group’s primary operations are centred in Germany, which is recognized as one
of Europe’s fastest growing medical cannabis markets. This growth is fuelled by increased
adoption among physicians, broader patient access, and a favourable regulatory
landscape following the 2024 cannabis law reform. The German medical cannabis market
was valued at over €2 billion in 2025, serving approximately 800,000 patients. The market
is forecast to surpass €4.5 billion by 2028 expecting a 50% year-over-year growth rate,
with the patient population expected to reach around 1.8 million (~2.0% of the population),
bringing it on par with other major global medical markets, such as Israel (1.9%) and
Australia (2.3%)
2
.
Sanity Group Highlights
• Year-over-year net revenue growth, from €9 million in calendar 2023 to €19
million in 2024 to €60 million in 2025, including €19 million generated in the last
quarter of calendar 2025. 2026 year-to-date results show a continued growth
trend.
• Gross margin improvement, from 15% in 2023 to 35% in 2024 to 47% in 2025.
• Estimated #2 market share position as of January 2026, up from #5 in January
2025
2
.
• Strategically expanding European footprint beyond Germany and Switzerland
including Poland, the UK, and Czechia.
• Currently operates two locations in Swiss pilot program, with growing study
participant numbers.
• Deep European regulatory expertise and network, critical to navigating markets,
regulatory frameworks and intelligence as the market expands.
“I am truly excited to embark on this new chapter as our company joins forces with
Organigram. Sanity’s strong focus in Europe is highly complementary to Organigram’s
strengths, and I have tremendous confidence in their vision and ambitious business plan
to scale internationally. Together, we are poised to unlock significant growth
opportunities, especially as new European markets open to both medical and recreational
2
Source: Euromonitor, Australian Institute of Health and Welfare, Israel Health Ministry, Market Estimates (Europe)
cannabis programs. Organigram has already proven to be an exceptional partner,
bringing deep expertise in areas such as cultivation, manufacturing, R&D, and innovation.
These strengths will be vital as we collectively shape the rapidly expanding global
cannabis landscape” said Finn Age Hänsel, CEO of Sanity Group.
Strategic Rationale for the Acquisition
“Organigram’s proven track record in executing highly strategic and complementary M&A
is exemplified by our proposed acquisition of Sanity Group—a transaction that is both
strategically significant and financially accretive. By combining our strengths as focused
cannabis pure play companies, we will be well-positioned to deliver meaningful value for
our shareholders and accelerate growth in key European markets. We are truly excited
about the opportunities ahead with this acquisition as we are now poised to set a new
standard in the global cannabis sector together,” said Paolo De Luca, Chief Strategy
Officer at Organigram.
Acquisition Highlights:
-
Financially accretive acquisition that is expected to bring scale and
positively impact both revenue and profitability. Sanity generated positive
EBITDA in 2025.
-
Cements Organigram’s position as a leader in the growing global cannabis
market. Organigram is currently #1 in the Canadian adult use recreational
market
3
, and on closing will become a top company in the rapidly growing German
medical cannabis market, the second largest federally legal cannabis market in the
world after Canada.
-
Provides Organigram with a vertically integrated European ‘hub’ and
footprint. Will add local leadership, a strong network of strategic partners
throughout the value chain across Europe as well as commercial, operational,
medical and regulatory expertise.
-
Sanity Group operates Europe’s first two legal cannabis specialty stores as
part of scientific pilot projects in Switzerland. Pilot project experience also
enhances credibility for future pilot projects, including in Germany.
-
Provides Organigram the opportunity to bring its industry leading brands
and IP to new markets globally. The combination of both teams, with the support
of the Product Development Collaboration (PDC) generated IP, is expected to
deliver a suite of next generation cannabis innovations, backed by science, to
European medical markets.
3
HiFyre, January 2026 (Canada)
Deal Valuation, Structuring of Consideration and Earnout
Valuation,
Structuring and
Earnout
Upfront
(in millions)
Maximum
Contingent
(in millions)
Total Potential
(in millions)
Cash Consideration
1
€80.0 ($129.6) €20.0 ($32.4) €100.0 ($162.0)
Share Consideration 33.4 (54.1) 93.8 (152.0) 127.2 (206.0)
Total to be Paid 113.4 (183.7) 113.8 (184.4) 227.2 (368.0)
Organigram Interests 16.6 (26.9) 6.2 (10.0) 22.8 (37.0)
Total Valuation €130.0 ($210.6) €120.0 ($194.4) €250.0 ($405.0)
Sanity completed 2025 with net revenue of €19 million for the last quarter which, at a €130
million upfront valuation, results in a last quarter annualized (LQA) multiple of 1.7x. Based
on Sanity and Germany’s historic growth rate and Euromonitor’s forecast of the Germany
market doubling by 2028, Organigram expects net revenue to average approximately €25
million for the last three calendar quarters of 2026. Based on tightening competitive
pressures in the German market initial expectations of gross margins of ~39% to 40%
and adjusted EBITDA margins
4
of 10% to 12% are targeted.
The Earnout Consideration will be calculated using a notional Sanity valuation (“Sanity
Valuation”), which will be arrived at by weighing net revenue and EBITDA each by 50%
after multiplying them by 1.75 and 12.5 times respectively for the 12-month period
following closing (the “Earnout Period”)
5
. The notional Sanity Valuation will be capped at
€250 million inclusive of Organigram’s interests. The Earnout Consideration will be
calculated as the Sanity Valuation less the Upfront Valuation, adjusted for Organigram’s
interests, and will have a maximum payout to the Vendors of €113.8 million.
Earnout Consideration will be settled with a maximum of €20 million cash
1
and the
remainder in Organigram shares issued at the 20-day VWAP on the TSX subject to a
C$3.00 floor and C$4.00 cap.
As a condition precedent for any Earnout Consideration to be paid, Sanity must generate
a minimum amount of EBITDA during the Earnout Period so that Sanity is self-sustaining
from a cashflow perspective before consideration of working capital needs. Organigram
will make up to €10 million available to Sanity on closing of the Acquisition to fund working
capital needs in a high growth environment. To the extent that any of the €10 million is
not repaid by the end of the Earnout Period, the Earnout Consideration will be reduced
by the outstanding amount.
4
Refer to Organigram’s Q1-2026 calculation of adjusted EBITDA in its MD&A – in general the Sanity acquisition will have less IFRS
to adjusted EBITDA adjustments.
5
An indicative target net revenue of €143 million and target EBITDA of €20 million for the Earnout Period was modelled as one
example of achieving the full Earnout but the Earnout can be achieved through other combinations of net revenue and EBITDA.
Sources of Cash
Cash consideration to Sanity shareholders
1
will be funded through a combination of cash
on hand (restricted Jupiter funds), the Private Placement Investment, and the proceeds
of a credit facility with ATB Financial and a syndicate of lenders, in respect of which the
Company has entered into an underwritten commitment, subject to customary closing
conditions.
British American Tobacco plc (“BAT”) through its wholly owned subsidiary, BT DE
Investments Inc., is a shareholder in both Organigram and Sanity and has opted to take
Organigram share consideration in lieu of cash for its interest in Sanity.
Private Placement and Top Up Rights
Organigram is in advanced negotiations with BAT in respect of a C$65.2 million
investment (the “Private Placement Investment”) to be used to finance the cash
component of the Acquisition and for transaction expenses. The Private Placement
Investment is expected to be comprised of an exercise by BAT of certain existing top-up
rights (“Top-Up Rights”) and a private placement for Organigram shares.
ATB Financial Senior Secured Credit Facilities
ATB Financial, who is acting as sole lead arranger and bookrunner, provided a fully
underwritten commitment of the senior secured credit facilities (the “Loan Facilities”) of
up to $60 million. ATB will also act as administrative agent for the Loan Facilities.
The Loan Facilities include:
(a) $40 million senior secured facility comprised of a $10 million operating line and a
$30 million revolving credit facility; and
(b) $20 million senior secured non-revolving credit facility.
The Loan Facilities will be available on closing, subject to customary closing conditions,
and bear interest at ATB’s referenced benchmark rates plus a spread determined by
funded debt to trailing twelve month adjusted EBITDA. The Loan Facilities are subject to
normal course funded debt and fixed charge covenants.
Transaction Summary and Shareholder Approval Requirements
Pursuant to the Purchase Agreement, Organigram will indirectly acquire of all the issued
and outstanding shares of Sanity Group not currently owned by Organigram. Total
Upfront Consideration is €113.4 million (C$183.7 million), consisting of €80 million
(C$129.6 million) in cash
1
and €33.4 million (C$54.1 million) in Organigram shares. In
addition, the Vendors will be entitled to receive the Earnout Consideration. The Upfront
Consideration shares will be priced at C$3.00 per Organigram share, a 71% premium to
the C$1.75 closing price on the TSX on February 17, 2026 and the Earnout Consideration
shares shall be priced at the TSX 20-day VWAP on the trading day prior to settlement
subject to a C$3.00 floor and C$4.00 cap.
Organigram anticipates that the Acquisition, together with the Private Placement
Investment and the Credit Facility (each of which is or will be conditional upon completion
of the Acquisition) will close concurrently in the second quarter of 2026. Completion of
the Acquisition is subject to certain closing conditions, including, among other things,
receipt of all required regulatory approvals, including approval of the TSX and clearance
under Germany’s foreign direct investment regime from the German Federal Ministry for
Economic Affairs and Energy, and other customary closing conditions for a transaction of
this nature. Organigram’s obligation to complete the Acquisition is subject to the additional
conditions, including approval of the Acquisition by Organigram’s shareholders and the
arrangement by Organigram, on terms and conditions satisfactory to it, of third-party
financing, in an amount sufficient to pay the cash
1
portion of the purchase price payable
under the Purchase Agreement, which is expected to be satisfied by the closing of the
Private Placement Investment and Credit Facilities.
The Company is required to obtain disinterested shareholder approval (50.1% of shares
voting at the meeting, excluding any shares held by BAT) for the Acquisition under
Subsections 611(c) and 604(a)(ii) of the TSX Company Manual, as the total number of
shares to be issued as part of the Upfront Consideration and pursuant to the Private
Placement Investment (i) will exceed 25% of Organigram’s current shares outstanding,
and (ii) will result in the value of consideration issued to BAT, an insider of the Company,
exceeding 10% of the Company’s market capitalization.
In addition to the above, the Acquisition and the Private Placement Investment will
constitute “related party transactions” under Multilateral Instrument 61-101 - Protection of
Minority Security Holders in Special Transactions (“MI-61-101”) and will require “majority
of the minority” approval under MI 61-101, being approval by a simple majority of votes
cast by the shareholders of Organigram, excluding any votes attached to the shares held
by BAT.
The Company intends to obtain the requisite shareholder approval at its annual and
special shareholders’ meeting to be held on March 30, 2026.
Private Placement Investment Details
Pursuant to the Private Placement Investment, BAT is expected to subscribe for
14,027,074 Organigram shares at a price of C$3.00 per share, for gross proceeds of
C$42.08 million, the proceeds of which will be used to fund the Acquisition, and to also
exercise certain Top-Up Rights to subscribe for 9,897,356 Organigram shares at a price
of C$2.335854 per share, for gross proceeds of C$23.12 million.
The closing of the Private Placement Investment is expected to be subject to the closing
of the Acquisition, as well as the receipt of certain regulatory approvals, approval from
Organigram’s shareholders and other customary conditions for a transaction of this
nature.
To the extent BAT’s ownership of shares in the Company exceeds 30.0% of the total
issued and outstanding common shares of the Company on a post-issuance basis, BAT
would, in lieu of common shares, be issued non-voting Class A convertible preferred
shares of Organigram (“Preferred Shares”). Based on Organigram’s current 135,132,782
Common Shares outstanding, BAT would be issued 2,353,379 Common Shares and
21,571,051 Preferred Shares pursuant to the Private Placement Investment. The
Preferred Shares would be eligible for conversion into voting Common Shares in
accordance with their terms, provided that such conversion would not result in BAT’s
voting interest in the Company exceeding 30%.
Pro-Forma Capitalization Table (Basic Only)
6
Pro-Forma
Capitalization
Table
December
31, 2025
Sanity
Acquisition
(Upfront
Only)
Pro-Forma –
Upfront Only
Earnout
(assuming
Maximum
Payable)
7
Pro-Forma
Assuming
Maximum
Payout
Sanity Investors
(excluding
Organigram and
BAT)
4,139,758
(2.9%, 2.2%)
35,219,054
39,358,812
(21.6%, 16.7%)
Existing
Organigram
Shareholders
(excluding BAT)
94,998,393
(70.3%, 63.3%)
94,998,393
(67.1%, 49.4%)
94,998,393
(52.2%, 40.2%)
BAT Common
Share Holdings
40,134,389
(29.7%, 26.7%)
2,353,379
42,487,768
(30.0%, 22.1%)
5,300,447
47,788,215
(26.2%, 20.2%)
6
Percent (%) holdings in parenthesis reflect holdings as % of common shown first and % of common and preferred second except
second last row which reflects % of common and preferred only.
7
Under the maximum earnout Organigram has initially calculated issuing 40.5 million shares at an assumed $3.75 share price. With
a $3.00 floor and $4.00 cap for Earnout Shares Organigram would be required to issue a maximum of 50.6 million shares and a
minimum of 38.0 million shares respectively.
Total Common
Shares
135,132,782 6,493,137 141,625,919 40,519,501 182,145,420
BAT Preferred
Shares Including
Accretion
14,994,047
(10.0%)
35,553,554
50,527,600
(26.3%)
3,789,570
54,317,170
(23.0%)
Total Common &
Preferred Shares
(including accretion
on Preferred
Shares)
150,126,829 192,153,520 236,462,591
Board of Directors Approval and Opinion Received
BMO Capital Markets has provided an oral opinion to the Investment Committee of the
Board and the Board to the effect that, as of the date of such opinion, and subject to the
assumptions, limitations and qualifications to be set forth in its written opinion, the
consideration to be paid by the Company pursuant to the Purchase Agreement is fair,
from a financial point of view, to the Company (the “Opinion”).
After considering the Opinion and the advice of its financial and legal advisors, among
other factors, the Board has unanimously determined that the Acquisition and the Credit
Facility are in the best interests of Organigram with BAT’s nominees to the Board
declaring an interest in such matters thereby abstaining from the vote. .
8
Additional Information Regarding the Acquisition and Private Placement
Investment
Copies of the Purchase Agreement and the definitive agreement governing the Private
Placement Investment and a material change report containing additional information
regarding the Acquisition and the Private Placement Investment will be filed on
Organigram’s SEDAR+ profile at www.sedarplus.ca and filed or furnished to the
Securities and Exchange Commission on EDGAR (see www.sec.gov). This press release
is only a summary of certain principal terms of the Acquisition and is qualified in its entirety
by reference to the more detailed information contained in the material change report.
Advisors and Counsel
In connection with the Acquisition, Organigram engaged EY for financial and tax advisory
work, BMO Capital Markets to provide the Fairness Opinion, Hogan Lovells LLP as its
local legal counsel in Germany, and Goodmans LLP as its Canadian legal counsel. Sanity
Group engaged its former Managing Director and Chief Investment & Strategy Officer
Max Narr for the management of the Acquisition and Rothschild as its exclusive financial
advisor. Katharina Erbe (RSR) and Patrick Biagosch (Biagosch Partner) acted as its
legal counsel in Germany and McMillan LLP as its legal counsel in Canada. BAT
engaged Stikeman Elliott LLP as its legal counsel in Canada in connection with the
Private Placement Investment.
Investor Presentation
To view the Investor Presentation, please click this link: Investor Presentation
About Organigram
Organigram Global Inc. is a NASDAQ Global Select Market and TSX listed company
whose wholly owned subsidiary, Organigram Inc., is a licensed cultivator of cannabis and
manufacturer of cannabis-derived goods in Canada. Through its acquisition of Collective
Project Limited, Organigram Global participates in the U.S. and Canadian cannabinoid
beverage markets. Organigram is focused on producing high-quality cannabis for adult
consumers, as well as developing international business partnerships to extend the
Company's global footprint. Organigram has also developed and acquired a portfolio of
cannabis brands, including Edison, Big Bag O’ Buds, SHRED, SHRED’ems, Monjour,
Tremblant Cannabis, Collective Project, Trailblazer, BOXHOT and DEBUNK. Organigram
operates facilities in Moncton, New Brunswick and Lac Supérieur, Quebec, with a
dedicated edibles manufacturing facility in Winnipeg, Manitoba. The Company also
operates two additional cannabis processing facilities in Southwestern Ontario; one in
Aylmer and the other in London. The facility in Aylmer houses best-in-class CO2 and
Hydrocarbon extraction capabilities, and is optimized for formulation refinement, post-
processing of minor cannabinoids, and pre-roll production. The facility in London will be
optimized for labelling, packaging, and national fulfillment. The Company is regulated by
Health Canada under the Cannabis Act and the Cannabis Regulations (Canada).
About Sanity Group
Sanity Group aims to improve people’s quality of life through the use of cannabinoids and
the utilization of the endocannabinoid system. The focus is on cannabinoid-based
pharmaceuticals and consumer goods. To harness the full potential of cannabis, Sanity
Group invests in research of the cannabis plant and its active ingredients as well as in
specific areas of application. Sanity Group, co-founded in Berlin in 2018 by Finn Age
Hänsel, includes Vayamed, avaay Medical and ZOIKS (medical cannabis), Endosane
Pharmaceuticals (finished pharmaceuticals), vaay (lifestyle) and Grashaus Projects
(recreational cannabis Swiss pilot project). Near Frankfurt am Main, Sanity Group also
operates a logistics and production facility for cannabis pharmaceuticals. More
information at sanitygroup.com/press.
Forward-Looking Information
This news release contains forward-looking information. Often, but not always, forward-
looking information can be identified by the use of words such as “plans”, “expects”,
“estimates”, “intends”, “anticipates”, “believes” or variations of such words and phrases or
state that certain actions, events, or results “may”, “could”, “would”, “might” or “will” be
taken, occur or be achieved. In addition, any statements that refer to expectations,
projections or other characterizations of future events or circumstances contain forward-
looking-statements. Forward-looking information involves known and unknown risks,
uncertainties and other factors that may cause actual results, events, performance or
achievements of Organigram to differ materially from current expectations or future
results, performance or achievements expressed or implied by the forward-looking
information contained in this news release. Specifically, statements regarding the
expected closing of the Acquisition, the sources of funds to finance the Acquisition, the
terms of the Private Placement Investment, the expected benefits of the Acquisition, the
future business prospects of Organigram, and Organigram’s expectations in respect of
net revenue for 2026 are forward-looking statements. In calculating net revenue for 2026
and making statements about Sanity’s financial performance, the Company has made
assumptions that are based on presumed growth rates in Germany, Sanity continuing to
hold one of the top market share positions, continued availability of flower supply from
Canadian and other international cultivators, and market conditions, pricing and margins
not deteriorating beyond the already forecasted reduction in gross margins. Such
assumptions are based on management's assessment of the relevant information
currently available and any financial outlook included herein is provided for the purpose
of helping readers understand management's current expectations and plans for the
future as of the date hereof.
Risks, uncertainties and other factors involved with forward-looking information could
cause actual events, results, performance, prospects and opportunities to differ materially
from those expressed or implied by such forward-looking information. Forward-looking
statements reflect current beliefs of management of the Company with respect to future
events and are based on information currently available to management including the
reasonable assumptions, estimates, analysis and opinions of management of the
Company considering their experience, perception of trends, current conditions and
expected developments as well as other factors that management believes to be relevant
as at the date such statements are made, including, but not limited to, that the Company
will come to terms with BAT in respect of the Private Placement Investment, that
shareholders will vote to approve the Acquisition and the Private Placement Investment,
and that the conditions to closing the Acquisition, the Private Placement Investment and
the Credit Facility will be satisfied within a reasonable period of time or at all. Forward-
looking statements involve significant known and unknown risks and uncertainties. Many
factors could cause actual results, performance or achievement to be materially different
from any future forward-looking statements. There is a risk that one or more of the
Acquisition, the Private Placement Investment and/or the Credit Facility does not close or
close within the expected timeline. There is a risk that some or all the expected benefits
of the Acquisition may fail to materialize or may not occur within the time periods
anticipated by the Company. The challenge of coordinating previously independent
businesses makes evaluating the business and future financial prospects of the Company
following the business combination difficult. Material risks and uncertainties that could
cause actual results to differ from forward-looking statements include not receiving
approval for the Acquisition and Private Placement Investment from the shareholders, not
receiving any of the regulatory approvals (including approval from the TSX and foreign
direct investment clearance from the German Federal Ministry for Economic Affairs and
Climate Action) required to close the Acquisition and Private Placement Investment, the
timing and outcome of any such regulatory review negatively impacting the Acquisition,
that all conditions to the closing of the Purchase Agreement will not be satisfied, that the
Acquisition will not be completed on the terms set forth in the Purchase Agreement, that
the Acquisition will not close, inherent uncertainty associated with the financial and other
projections (including projections relating to revenue, EBITDA, valuation and earnout
calculations) as well as market and regulatory changes arising that reduce or eliminate
the benefits of the Acquisition; the effective integration of Sanity into the Company not
being possible; the ability to achieve the anticipated synergies and value-creation
contemplated by the business combination not being possible or being delayed; the
response of business partners and retention as a result of the business combination being
negative; the impact of competitive responses to the business combination negatively
impacting the Company; the ability to achieve the expected manufacturing and production
output including flower supply not being possible; the risk that Sanity may not achieve the
financial performance thresholds required for the payment of some or all of the Earnout
Consideration; and the diversion of management time on business combination-related
issues. Readers are cautioned that the foregoing list of factors is not exhaustive. Other
risks and uncertainties not presently known to the Company or that the Company
presently believe are not material could also cause actual results or events to differ
materially from those expressed in the forward-looking statements contained herein. For
a more detailed discussion of risks and other factors, see the factors and risks disclosed
in the Company’s most recent annual information form, management’s discussion and
analysis and other Company documents filed from time to time on SEDAR+ (see
www.sedarplus.ca) and filed or furnished to the Securities and Exchange Commission on
EDGAR (see www.sec.gov). Readers are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date of this press release.
Although the Company believes that the assumptions and factors used in preparing the
forward-looking information in this news release are reasonable, undue reliance should
not be placed on such information, and no assurance can be given that such events will
occur in the disclosed time frames or at all. The forward-looking information included in
this news release are made as of the date of this news release and the Company
disclaims any intention or obligation, except to the extent required by law, to update or
revise any forward-looking information, whether as a result of new information, future
events or otherwise.
For Organigram Media enquiries:
Sonia Prashar
[email protected]
For Organigram Investor Relations enquiries:
Max Schwartz
Director of Investor Relations
[email protected]